Structure Therapeutics Inc (GPCR) Stock Price, Quote & News

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 457 1978

Website: structuretx.com

Address:

601 Gateway Boulevard, Suite 900, South San Francisco, United States

BioRich Jan. 26 at 4:39 AM

$XBI $XBI Top 12 for the week ahead (9-12) 9) $GPCR 10) $KYTX 11) $CCCC 12) $IBRX Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

0 · Reply

Kylenorth Jan. 23 at 7:49 PM

$GPCR buy those dips!!

0 · Reply

norbertm Jan. 23 at 6:03 PM

$GPCR $ALT “Next up in weight loss drugs: More pills, easier access and drug combinations”: https://www.cnbc.com/2026/01/23/weight-loss-glp-1-drugs-next-steps-for-eli-lilly-novo-nordisk-pfizer.html

0 · Reply

Theflash88 Jan. 23 at 5:34 PM

$GPCR Added here.

0 · Reply

Artster25 Jan. 23 at 2:44 PM

$GPCR this week ALT is having its GPCR moment ! Check it out.

0 · Reply

DenisseEllisonQ Jan. 23 at 12:46 PM

$GPCR biotech small cap coil with asymmetry if catalysts drive volume

0 · Reply

norbertm Jan. 22 at 8:19 PM

$GPCR relatively low volume. Profit taking and short covering at ATH, pot met kettle. IMHO.

0 · Reply

DavidT305 Jan. 22 at 7:37 PM

$GPCR they’re saying end 2028 for phase 3 data, who would wait around for that? That’s like 2030 before its available. Retratutide is getting approved in 2027, way more effective than this. There’s a good possibility gpcr data is going to be worse than lly pill in a larger phase 3 w dropouts.

1 · Reply

norbertm Jan. 22 at 2:40 PM

$GPCR I think 100$ is on deck, then consolidation around. Retail own 10% and profit taking is pretty much expected at each 3-5% swings.

1 · Reply

norbertm Jan. 21 at 11:53 PM

$GPCR By the end of December this had 6M shares sold short (roughly 10% of float). Price was in the 60-70 range in December (with a peak at 95 intraday on December 8). This is held and traded mostly by hedge funds and institutions. Are we witnessing short capitulation? I think so personnally.

0 · Reply

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Jan 15, 2026, 6:21 PM EST - 11 days ago

Structure CEO Ray Stevens talks its obesity drug portfolio

Dec 11, 2025, 4:01 PM EST - 6 weeks ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 9, 2025, 11:15 PM EST - 6 weeks ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 8:30 AM EST - 7 weeks ago

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Dec 8, 2025, 7:27 PM EST - 7 weeks ago

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Dec 8, 2025, 5:18 PM EST - 7 weeks ago

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Dec 8, 2025, 4:01 PM EST - 7 weeks ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 12:46 PM EST - 7 weeks ago

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Dec 8, 2025, 11:20 AM EST - 7 weeks ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 8:14 AM EST - 7 weeks ago

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:00 AM EST - 7 weeks ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 7, 2025, 6:20 PM EST - 7 weeks ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Nov 10, 2025, 6:21 PM EST - 2 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Nov 6, 2025, 4:01 PM EST - 2 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 5, 2025, 6:21 PM EST - 2 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Sep 10, 2025, 1:54 PM EDT - 4 months ago

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 6, 2025, 4:01 PM EDT - 6 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Jun 23, 2025, 6:10 PM EDT - 7 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Jun 20, 2025, 7:30 PM EDT - 7 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Apr 14, 2025, 10:49 AM EDT - 10 months ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Mar 27, 2025, 7:40 AM EDT - 10 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Mar 24, 2025, 6:26 PM EDT - 11 months ago

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:23 PM EDT - 11 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Mar 20, 2025, 9:28 AM EDT - 11 months ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 6, 2025, 2:53 PM EST - 1 year ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Oct 22, 2024, 2:07 PM EDT - 1 year ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 4:09 PM EDT - 1 year ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 2:38 PM EDT - 1 year ago

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 8:42 AM EDT - 1 year ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

May 7, 2024, 11:33 AM EDT - 1 year ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Apr 16, 2024, 7:09 PM EDT - 1 year ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Mar 9, 2024, 2:30 AM EST - 2 years ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Mar 8, 2024, 4:05 PM EST - 2 years ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 8:30 AM EST - 2 years ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

BioRich Jan. 26 at 4:39 AM

0 · Reply

Kylenorth Jan. 23 at 7:49 PM

$GPCR buy those dips!!

0 · Reply

norbertm Jan. 23 at 6:03 PM

0 · Reply

Theflash88 Jan. 23 at 5:34 PM

$GPCR Added here.

0 · Reply

Artster25 Jan. 23 at 2:44 PM

$GPCR this week ALT is having its GPCR moment ! Check it out.

0 · Reply

DenisseEllisonQ Jan. 23 at 12:46 PM

$GPCR biotech small cap coil with asymmetry if catalysts drive volume

0 · Reply

norbertm Jan. 22 at 8:19 PM

$GPCR relatively low volume. Profit taking and short covering at ATH, pot met kettle. IMHO.

0 · Reply

DavidT305 Jan. 22 at 7:37 PM

1 · Reply

norbertm Jan. 22 at 2:40 PM

$GPCR I think 100$ is on deck, then consolidation around. Retail own 10% and profit taking is pretty much expected at each 3-5% swings.

1 · Reply

norbertm Jan. 21 at 11:53 PM

0 · Reply

Pajohnamo Jan. 21 at 11:12 PM

$GPCR 99% getting bought out

3 · Reply

Kylenorth Jan. 21 at 9:13 PM

$GPCR all time closing high!! worth 3 billion more than the loser $VKTX

0 · Reply

Kylenorth Jan. 21 at 8:34 PM

$GPCR keeps paying!! 200 this year!! every share is being bought!!!

0 · Reply

DavidT305 Jan. 21 at 6:20 PM

$GPCR this is the most surprising biotech stock the last yr. Their data is going be worse in phase 3, lly had the same numbers in phase 2 then dropped with a larger phase 3 where you have to include dropouts data in the stats. The government price controls are the other problem

0 · Reply

biolover Jan. 21 at 5:44 PM

$GPCR $VKTX good luck with your GPCR investment. Watch when h can get in and out.

2 · Reply

inv1ncible Jan. 21 at 5:38 PM

$VKTX so much love for $GPCR but jot here 🙄🫩😑

0 · Reply

DatFuwKinGuy Jan. 21 at 4:36 PM

$GPCR pump and dump

0 · Reply

norbertm Jan. 21 at 4:01 PM

$GPCR I am looking forward to this smashing through 95$ (intraday high it hit 6 weeks back).

1 · Reply

Kylenorth Jan. 21 at 3:46 PM

$GPCR all time high today!! haha smash the shitty $VKTX nerd losers

0 · Reply

Ms_P Jan. 21 at 2:59 PM

$GPCR was thinking about selling this, but considering that generalists are now getting into biotech. I’m going to hold on a bit longer (long since $31). Generalists are finally realizing that there are elements with biotech that are more or less immune to short term economic events (ie: M&A frenzy from big pharma procrastination on patent cliff mitigation). https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/

0 · Reply

Kylenorth Jan. 21 at 2:38 PM

$GPCR buy any dips!!!

0 · Reply

trreport Jan. 21 at 3:39 AM

$GPCR Some good volumes above $94 in the overnight market. A rally in the market could get this above 100 today.

0 · Reply

Market Cap	5.48B
Revenue (ttm)	0.00
Net Income (ttm)	-122.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	479,300
Avg Vol	1,794,968
Day's Range	N/A - N/A
Shares Out	60.68M
Stochastic %K	80%
Beta	-2.05
Analysts	Strong Sell
Price Target	$107.80